PMV Pharmaceuticals
PMVP
69 hedge funds and large institutions have $45.8M invested in PMV Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
10% more funds holding
Funds holding: 63 → 69 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $46.8M → $45.8M (-$941K)
1.02% less ownership
Funds ownership: 70.33% → 69.31% (-1%)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$2.99M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.37M |
| 3 |
Two Sigma Investments
New York
|
+$1.5M |
| 4 |
Morgan Stanley
New York
|
+$973K |
| 5 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$702K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$6.22M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$884K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$563K |
| 4 |
Jane Street
New York
|
-$476K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$438K |
PMVP Hedge Fund Activity: Q1 2026 in Review
69 of the 8,141 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2026, worth a combined $45.8M — down 2% from $46.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PMVP positions and 8 closed out — a net gain of 7 holders — while 16 added to existing stakes and 20 trimmed.
The largest buyer was Eversept Partners, opening a new position worth an estimated $2.99M. The largest seller was OrbiMed, exiting entirely with an estimated $6.22M sold.
- 69 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2026, up from 63 in Q4 2025.
- Funds reported $45.8M of PMV Pharmaceuticals stock for Q1 2026, down 2% quarter-over-quarter.
- 15 funds opened new PMV Pharmaceuticals positions in Q1 2026 and 8 closed out, a net change of +7 holders.
- The largest PMV Pharmaceuticals buyer in Q1 2026 was Eversept Partners, an estimated $2.99M added.
- The largest PMV Pharmaceuticals seller in Q1 2026 was OrbiMed, an estimated $6.22M sold.
Based on aggregated 13F filings for Q1 2026.